Our Pricing

Wegovy Doses Explained: Get Your Online Prescription Today

Published on: June 03, 2026

Understanding wegovy doses UK online prescription requirements is essential before starting treatment. At Cured Pharmacy, our UK-registered clinical team guides you through the complete dose escalation schedule, from the 0.25mg starting dose to the 2.4mg maintenance dose, with transparent pricing from £79.00 and free online consultation.

Understanding Wegovy Doses UK: The Complete Escalation Schedule

Wegovy (semaglutide) follows a carefully structured dose escalation schedule designed to minimise gastrointestinal side effects whilst maximising weight loss efficacy [1]. The treatment begins at 0.25mg weekly and gradually increases over 16 weeks to the maintenance dose of 2.4mg weekly.

This gradual titration approach was developed through the STEP clinical trial programme, where participants following the full escalation schedule experienced significantly fewer treatment discontinuations due to side effects compared to rapid dose increases [1]. Each dose strength is maintained for four weeks before progressing to the next level, allowing your body to adapt to the medication.

The complete Wegovy dosing schedule approved by the MHRA includes: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg (week 17 onwards) [2]. Your UK prescriber may adjust this schedule based on your individual tolerance and clinical response during your treatment journey.

Wegovy Starting Dose: What to Expect in Your First Month

The initial Wegovy starting dose of 0.25mg weekly serves primarily as a tolerance-building phase rather than a therapeutic dose [1]. During this first month, you may notice modest appetite reduction, but the primary goal is allowing your gastrointestinal system to adapt to semaglutide's effects on gastric emptying.

Clinical experience from thousands of UK patients shows that those who maintain the 0.25mg dose for the full four weeks experience significantly fewer nausea and vomiting episodes when progressing to 0.5mg [2]. Rushing through this initial phase increases the likelihood of treatment discontinuation.

At Cured Pharmacy, our UK prescribers provide detailed guidance on injection technique, timing, and dietary modifications during your starting dose phase. All prescription treatments require clinical assessment, and your prescriber will confirm the appropriate starting dose based on your medical history and current medications.

Common Side Effects During the Starting Dose Phase

During the 0.25mg starting dose, approximately 44% of patients in the STEP trials reported mild gastrointestinal symptoms, predominantly nausea and occasional constipation [1]. These effects typically resolve within 7-10 days as your body adjusts to the medication. Eating smaller, more frequent meals and avoiding high-fat foods can significantly reduce symptom severity during this adaptation period.

Wegovy Dose Escalation: Weeks 5-16 Explained

The intermediate escalation phases at 0.5mg, 1mg, and 1.7mg represent the critical weight loss acceleration period [2]. Data from the STEP-1 trial demonstrated that participants achieved approximately 60% of their total weight loss during this 12-week escalation window, with average reductions of 9.6% body weight by week 16 [1].

Each four-week dose plateau allows semaglutide plasma concentrations to reach steady state before the next increase. Your UK prescriber may extend any dose level by an additional four weeks if you experience persistent side effects or require more gradual adaptation. This flexible approach, whilst extending the time to maintenance dose, often improves long-term treatment adherence.

The 1.7mg dose level is particularly significant as it represents the highest dose of semaglutide previously available in the UK market for diabetes management. Many patients achieve substantial weight loss at this level, and your prescriber may consider maintaining this dose if you reach your clinical goals before progressing to 2.4mg.

When Your Prescriber May Pause Dose Escalation

UK prescribers may temporarily hold dose escalation if you experience moderate-to-severe nausea lasting beyond two weeks, signs of dehydration, or significant changes in your eating patterns that raise concerns about adequate nutrition [2]. This is a standard clinical practice and does not indicate treatment failure. Remaining at a lower dose for an extended period can still produce meaningful weight loss whilst you address tolerability issues.

Wegovy Maintenance Dose: The 2.4mg Weekly Injection

The Wegovy maintenance dose of 2.4mg weekly represents the therapeutic target dose that produced the landmark results in the STEP clinical programme [1]. In the STEP-1 trial, participants receiving 2.4mg semaglutide achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo — a clinically significant difference that led to MHRA approval [1].

Once you reach the 2.4mg maintenance dose, you continue this weekly injection indefinitely as long as treatment remains clinically appropriate and well-tolerated. Wegovy is designed as a long-term weight management medication, not a short-term solution. Clinical data shows that discontinuing treatment typically results in gradual weight regain, with participants in the STEP-1 withdrawal extension regaining approximately two-thirds of their lost weight within one year of stopping [2].

At Cured Pharmacy, we provide ongoing prescription support for your maintenance dose therapy at competitive UK pricing from £79.00. Our UK-registered clinical team conducts regular medication reviews to assess your continued response, monitor for any emerging side effects, and adjust your treatment plan as needed. All prescription renewals require clinical reassessment by a UK prescriber to ensure ongoing safety and efficacy.

Wegovy Dosing Schedule UK: Practical Administration Tips

Wegovy is administered as a subcutaneous injection once weekly, on the same day each week, at any time of day regardless of meals [2]. The pre-filled pen devices are designed for self-administration into the abdomen, thigh, or upper arm. Rotating injection sites reduces the risk of lipodystrophy and improves absorption consistency.

If you miss a dose and it has been fewer than five days since your scheduled injection day, administer the missed dose as soon as you remember. If more than five days have passed, skip the missed dose entirely and resume your regular schedule with the next planned injection [2]. Never double doses to compensate for a missed injection, as this significantly increases the risk of severe gastrointestinal side effects.

Store unopened Wegovy pens in the refrigerator between 2°C and 8°C until the expiration date printed on the label. Once in use, pens may be stored at room temperature (up to 30°C) or continued refrigeration for up to 28 days. Protect pens from direct sunlight and never freeze them, as freezing denatures the semaglutide protein and renders the medication ineffective.

Optimising Injection Technique for Better Results

Proper injection technique significantly impacts both comfort and medication efficacy. Allow the pen to reach room temperature before injecting (approximately 15-20 minutes out of the refrigerator) to reduce injection site discomfort. Pinch the skin gently, insert the needle at a 90-degree angle, and hold the pen in place for at least six seconds after pressing the dose button to ensure complete medication delivery. Your UK prescriber can provide detailed technique guidance during your consultation.

Wegovy Doses UK Online Prescription: Getting Started at Cured Pharmacy

Obtaining your Wegovy doses UK online prescription through Cured Pharmacy begins with a free clinical consultation that takes under three minutes to complete. Our UK-registered prescribers, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), review your medical history, current medications, and weight loss goals to determine if Wegovy is clinically appropriate for you.

All prescription medications require online clinical assessment by a UK prescriber before dispensing. Wegovy is licensed in the UK for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension or type 2 diabetes [2]. Your prescriber will verify you meet these clinical criteria and have no contraindications to semaglutide therapy.

Once approved, your prescription is dispensed from our UK-registered pharmacy (GPhC 9012511) with 100% discreet packaging and next-day delivery options available. We provide transparent upfront pricing from £79.00 with the exact cost determined by your prescribed dose. You'll receive your complete starting dose supply along with detailed administration instructions and access to ongoing clinical support throughout your treatment journey.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy 2.4 mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency (MHRA). Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
5. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed by the MHRA for weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, used alongside a reduced-calorie diet and increased physical activity.